(Q36622727)

15 August 2017

1 reference

title

Molecularly targeted therapy for melanoma: current reality and future options (English)

1 reference

15 August 2017

1

Jürgen C Becker

1 reference

15 August 2017

4

Reinhard Dummer

1 reference

15 August 2017

6

Axel Hauschild

1 reference

15 August 2017

John M Kirkwood

2

1 reference

15 August 2017

Sanjiv S Agarwala

series ordinal

3

1 reference

15 August 2017

David Schrama

series ordinal

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

107

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

2317-2327

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

15 August 2017

1 reference

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Melanoma genetics and the development of rational therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Molecular targets in melanoma from angiogenesis to apoptosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Oncogenes in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Genetic pathways to melanoma tumorigenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Improving outcomes in advanced malignant melanoma: update on systemic therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Cutaneous side-effects of kinase inhibitors and blocking antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Targeting the molecular target of rapamycin (mTOR).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The ubiquitin-proteasome pathway and its role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The development of proteasome inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Overview of cancer epigenetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

DNA methylation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22273

1 reference

7 January 2021

Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The INK4a/ARF locus and melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

DNA methylation and cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

DNA methyltransferase inhibitors and the development of epigenetic cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Mechanisms and future directions for angiogenesis-based cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The clinical potential of antiangiogenic fragments of extracellular matrix proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Immunomodulation by thalidomide and thalidomide analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Phase II study of thalidomide in patients with metastatic malignant melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

A reevaluation of integrins as regulators of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

When does the presence of the target predict response to the targeted agent?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

New targets, therapies, and toxicities: lessons to be learned

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22273

7 January 2021

Identifiers

DOI

10.1002/CNCR.22273

1 reference

15 August 2017

1 reference